135 -2 (40) 2022 — Oblokulov A.R. — CLINICAL FEATURES OF LIVER DAMAGE IN COVID-19

CLINICAL FEATURES OF LIVER DAMAGE IN COVID-19

Oblokulov A.R. Bukhara State Medical Institute named after Abu Ali ibn Sino

Resume

The ongoing coronavirus disease 2019 (COVID-19) pandemic poses a major threat to health systems worldwide. There is still little information on how infection affects to the liver, and on the significance of pre-existing liver disease as a risk factor for infection or severe disease. In addition, considerations regarding liver transplant patients, patients with hepatocellular carcinoma, or those on immunosuppressive therapy are being analyzed as information is collected.

Key words: COVID-19, SARS-CoV-2, liver, cytokine storm, C-reactive protein, D-dimer.

First page

676

Last page

687

For citation: Oblokulov A.R. CLINICAL FEATURES OF LIVER DAMAGE IN COVID-19 //New Day in Medicine 2(40)2022 676-687 https://clck.ru/ejqcx

LIST OF REFERENCES:

  1. Li G., Fan Y., Lai Y., et al. Coronavirus infections and immune responses. //J Med Virol. 2020;92(4):424–32.;
  2. Oblokulov A.R., Niyozov G.E. Clinical and epidemiological characteristics of patients with COVID-19 (2020) International Journal of Pharmaceutical Research, 12 (4), pp. 3749-3752.
  3. Elmurodova A.A. (2022) “Specific Features of the Hemostatic System in Covid-19”. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES 3, 82-85.;
  4. Oblokulov A.R., Husenova Z.Z., Ergashev M.M. (2021). Procalcitonin as an indicator of antibacterial therapy in covid-19. Annals of the Romanian Society for Cell Biology, 5220-5224.
  5. Cuker A., Peyvandi F. Coronavirus disease 2019 (COVID-19): Hypercoagulability. Literature review, 2020.
  6. Connors J.M., Levy J.H. Thromboinflammation and the hypercoagulability of COVID-19 // J. Thromb. Haemost. 2020 // www.hematology.org/covid-19/covid-19-and-coagulopathy.;
  7. Облокулов А.Р., Ниезов Г.Э., Ражабов А.Р. Covid-Ассоциированная Коагулопатия У Пациентов Новой Коронавирусной Инфекции //CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. – 2021. – С. 124-130.
  8. Mclntosh K. Coronavirus disease 2019 (COVID-19): epidemiology, virology, clinical features, diagnosis, and prevention. Literature review, 2020.;
  9. Abdurashid Rahimovich Oblokulov, Zilola Zohirovna Husenova, Maksudjon Muzaffarovich Ergashev. (2021). Procalcitonin as an Indicator of Antibacterial Therapy in Covid-19. Annals of the Romanian Society for Cell Biology, Volume 25: Issue 3. 5220–5224
  10. Wu Z., McGoogan J.M. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention // JAMA. 2020.;
  11. Niyazov G.E., Oblokulov A.R., Pondina A.I. et al. (2020) Clinical and epidemiological characteristics of COVID-19 patients // New Day in Medicine. No. 4 (32) 110-115 p.
  12. Centers for Disease Control and Prevention. People who are at higher risk for severe illness // www.cdc.gov/coronavirus/2019-ncov/ need-extra-precautions/people-at-higher-risk.html.
  13. Kane S.V. Coronavirus disease 2019 (COVID-19): issues related to gastrointestinal disease in adults. Literature review, 2020.
  14. Burgueño J.F., Reich A., Hazime H. et al. Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD // Inflamm. Bowel Dis. 2020. Vol. 26. № 6. P. 797.
  15. Zhang C., Shi L., Wang F.-S. Liver injury in COVID-19: management and challenges // Lancet Gastroenterol. Hepatol. 2020. Vol. 5. № 5. P. 428–430.
  16. Pirola C.J., Sookoian S. SARS‐CoV‐2 virus and liver expression of host receptors: putative mechanisms of liver involvement in COVID‐19 // Liver. Int. 2020.
  17. Cardoso F.S., Pereira R., Germano N. Liver injury in critically ill patients with COVID-19: a case series // Crit. Care. 2020. Vol. 24. № 1. P. 190.
  18. Uhlen M., Fagerberg L., Hallstrom B.M. et al. Proteomics. Tissue-based map of the human proteome // Science. 2015. Vol. 347. P. 6220.
  19. Chai X., Hu L., Zhang Y. et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection // bioRxiv. 2020.
  20. Li J., Fan J.G. Characteristics and mechanism of liver injury in 2019 coronavirus disease // J. Clin. Transl. Hepatol. 2020. Vol. 8. № 1. P. 13.

file

download